Patient characteristics at diagnosis and before venetoclax initiation
Variable . | At diagnosis . | Before venetoclax . |
---|---|---|
Age, median (range), y | 63.9 (38.0-86.9) | 69.0 (38.3-87.8) |
Gender, n (%) | ||
Male | 64 (79.0) | — |
Female | 17 (21.0) | |
MIPI score, n (%) | ||
Low risk | 10 (16.4) | 15 (22.1) |
Intermediate risk | 21 (34.4) | 17 (25.0) |
High risk | 30 (49.2) | 36 (52.9) |
Missing data | 20 | 13 |
Ki-67 | ||
>30%, n (%) | 38 (61.2) | 29 (76.3) |
Median (range), % | 40 (5-90) | 70 (5-95) |
Missing data | 19 | 43 |
Blastoid or pleomorphic, n (%) | ||
Yes | 22 (29.3) | 29 (44.7) |
No | 53 (70.7) | 36 (55.4) |
Missing data | 6 | 16 |
Complex karyotype, n (%) | ||
Yes | 21 (33.9) | 10 (35.7) |
No | 41 (66.1) | 18 (64.3) |
Missing data | 19 | 53 |
TP53alterations, n (%) | ||
Yes | 21 (48.8) | 10 (33.3) |
TP53 mutation | 9 (20.9) | 5 (16.7) |
Del 17p by fluorescence in situ hybridization | 10 (23.3) | 5 (16.7) |
Del 17p by conventional cytogenetics | 2 (4.7) | 0 |
No | 22 (51.2) | 20 (66.7) |
Missing data | 38 | 51 |
Variable . | At diagnosis . | Before venetoclax . |
---|---|---|
Age, median (range), y | 63.9 (38.0-86.9) | 69.0 (38.3-87.8) |
Gender, n (%) | ||
Male | 64 (79.0) | — |
Female | 17 (21.0) | |
MIPI score, n (%) | ||
Low risk | 10 (16.4) | 15 (22.1) |
Intermediate risk | 21 (34.4) | 17 (25.0) |
High risk | 30 (49.2) | 36 (52.9) |
Missing data | 20 | 13 |
Ki-67 | ||
>30%, n (%) | 38 (61.2) | 29 (76.3) |
Median (range), % | 40 (5-90) | 70 (5-95) |
Missing data | 19 | 43 |
Blastoid or pleomorphic, n (%) | ||
Yes | 22 (29.3) | 29 (44.7) |
No | 53 (70.7) | 36 (55.4) |
Missing data | 6 | 16 |
Complex karyotype, n (%) | ||
Yes | 21 (33.9) | 10 (35.7) |
No | 41 (66.1) | 18 (64.3) |
Missing data | 19 | 53 |
TP53alterations, n (%) | ||
Yes | 21 (48.8) | 10 (33.3) |
TP53 mutation | 9 (20.9) | 5 (16.7) |
Del 17p by fluorescence in situ hybridization | 10 (23.3) | 5 (16.7) |
Del 17p by conventional cytogenetics | 2 (4.7) | 0 |
No | 22 (51.2) | 20 (66.7) |
Missing data | 38 | 51 |